Sarcopenia - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 64 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Sarcopenia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Sarcopenia - Pipeline Review, H2 2014', provides an overview of the Sarcopenia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sarcopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sarcopenia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Sarcopenia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Sarcopenia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Sarcopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Sarcopenia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Sarcopenia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Sarcopenia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Sarcopenia Overview 7
Therapeutics Development 8
Pipeline Products for Sarcopenia - Overview 8
Pipeline Products for Sarcopenia - Comparative Analysis 9
Sarcopenia - Therapeutics under Development by Companies 10
Sarcopenia - Therapeutics under Investigation by Universities/Institutes 12
Sarcopenia - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Sarcopenia - Products under Development by Companies 15
Sarcopenia - Products under Investigation by Universities/Institutes 16
Sarcopenia - Companies Involved in Therapeutics Development 17
Calzada Limited 17
Cytokinetics, Inc. 18
GlaxoSmithKline plc 19
Myomics, Inc. 20
Myos Corporation 21
Neurotune AG 22
Novartis AG 23
PsiOxus Therapeutics, Ltd. 24
Regeneron Pharmaceuticals, Inc. 25
Sumitomo Dainippon Pharma Co., Ltd. 26
Sarcopenia - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
Agrin Biologic for Sarcopenia - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
AOD-9604 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
bimagrumab - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CK-2066260 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
MT-102 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
NEP-28 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
NT-345 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Protein for Musculoskeletal Disorders - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Recombinant Protein for Sarcopenia - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
REGN-1033 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
S-107 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Small Molecule for Sarcopenia - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecules to Inhibit JAK3 for Sarcopenia and Cachexia - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Sarcopenia - Recent Pipeline Updates 53
Sarcopenia - Dormant Projects 56
Sarcopenia - Discontinued Products 57
Sarcopenia - Product Development Milestones 58
Featured News & Press Releases 58
Mar 13, 2012: Calzada Announces Positive Results Of AOD9604 In Cartilage And Muscle Repair Models 58
Dec 14, 2011: Calzada Announces New Applications For AOD9604 58
Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference 59
Aug 02, 2011: Researchers At Columbia University Discover New Drug For Sarcopenia 60
Dec 16, 2010: Myotec Therapeutics Completes Merger With Hybrid BioSystems To Form PsiOxus Therapeutics 61
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 64
Disclaimer 64

List of Tables
Number of Products under Development for Sarcopenia, H2 2014 8
Number of Products under Development for Sarcopenia - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
Sarcopenia - Pipeline by Calzada Limited, H2 2014 17
Sarcopenia - Pipeline by Cytokinetics, Inc., H2 2014 18
Sarcopenia - Pipeline by GlaxoSmithKline plc, H2 2014 19
Sarcopenia - Pipeline by Myomics, Inc., H2 2014 20
Sarcopenia - Pipeline by Myos Corporation, H2 2014 21
Sarcopenia - Pipeline by Neurotune AG, H2 2014 22
Sarcopenia - Pipeline by Novartis AG, H2 2014 23
Sarcopenia - Pipeline by PsiOxus Therapeutics, Ltd., H2 2014 24
Sarcopenia - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2014 25
Sarcopenia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 26
Assessment by Monotherapy Products, H2 2014 27
Number of Products by Stage and Target, H2 2014 29
Number of Products by Stage and Mechanism of Action, H2 2014 31
Number of Products by Stage and Route of Administration, H2 2014 33
Number of Products by Stage and Molecule Type, H2 2014 35
Sarcopenia Therapeutics - Recent Pipeline Updates, H2 2014 53
Sarcopenia - Dormant Projects, H2 2014 56
Sarcopenia - Discontinued Products, H2 2014 57